Equillium’s immuno-inflammatory drug wins FDA’s orphan drug status; Vanda sues FDA for mandating lengthy dog study

February 7, 2019 sandiegobiotech News Comments Off on Equillium’s immuno-inflammatory drug wins FDA’s orphan drug status; Vanda sues FDA for mandating lengthy dog study
Equillium's immuno-inflammatory drug wins FDA's orphan drug status; Vanda sues FDA for mandating lengthy dog study
/

? San Diego-based Equillium has nabbed an orphan drug designation for EQ001 on the verge of beginning a Phase Ib/II for the immuno-inflammatory drug. Also known as itolizumab, the drug was in-licensed from India?s Biocon, which sells it in the country as a psoriasis treatment. Equillium $EQ, however, is focusing its US clinical work on the prevention and treatment of acute graft-versus-host disease ? a strategy that has allowed it to skip financing rounds and jump str

Related Articles

No Picture
Industry News

Novo helps birth startup advancing an AstraZeneca castoff with $15M; Japan’s Fuji Pharma wagers $50M on Alvotech’s biosimilars

December 18, 2018 sandiegobiotech Industry News, News Comments Off on Novo helps birth startup advancing an AstraZeneca castoff with $15M; Japan’s Fuji Pharma wagers $50M on Alvotech’s biosimilars

? With backing from Novo Holdings and a drug from AstraZeneca, Aristea Therapeutics is unveiling a $15 million Series A that will kickstart Phase II studies of its lead program, RIST4721. James Mackay, who used to run AstraZeneca-acquired Ardea Bioscie… […]

No Picture
News

China vows to continue speeding up drug approvals, expand tax cuts; Sorrento/Yuhan JV receives $40M financing

February 12, 2019 sandiegobiotech News Comments Off on China vows to continue speeding up drug approvals, expand tax cuts; Sorrento/Yuhan JV receives $40M financing

? In the latest move to spur introduction of new medicines, China has announced it will reduce the value-add tax on 21 rare disease drugs the same way it offered tax breaks to imported cancer drugs in April 2018. While good news to all drugmakers, the … […]

No Picture
News

Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot

May 6, 2019 sandiegobiotech News Comments Off on Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot

Derek Archila
? Esperion got a 15% bump on its stock price $ESPR this morning after the biotech reported that the FDA had said it didn?t expect to call an advisory panel together to review the newly accepted NDAs for bempedoic acid (BPA) and their bemp… […]